Treating patients based on immune subtypes
Abstract
This document provides methods and materials for treating patients following an assessment of immune subtypes such as an assessment of peripheral blood phenotypes. For example, methods and materials for treating a mammal having a medical condition after assessing a mammal's level of CD14 + /DR − cells (e.g., CD14 + /DR − monocytes) and level of CD4 + cells (e.g., CD4 + T cells) and classifying the mammal has being likely to experience a favorable or unfavorable medical outcome based at least in part on the mammal's level of CD14 + /DR − cells and level of CD4 + cells are provided.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . A method for treating cancer, wherein said method comprises administering, to a mammal identified as having cancer and an elevated level of CD14 + /DR − cells, (i) a chemotherapy with or without surgery and (ii) an anti-CTLA-4 antibody, Ipilumimab, or an anti-PD1 antibody.
3 . The method of claim 2 , wherein said mammal is a human.
4 . The method of claim 2 , wherein said cancer is glioblastoma or lymphoma.Join the waitlist — get patent alerts
Track US2019086415A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.